Gut microbe metabolite found to modulate heart disease risk through β2-adrenergic receptors

  • Post author:
  • Post category:uncategorized

Study identifies phenylacetylglutamine (PAGln), a gut microbiome metabolite, as a novel allosteric modulator of β2-adrenergic receptors, offering insights into its role in cardiovascular disease (CVD) risk.